Update shared on 05 Nov 2025
Analysts have modestly increased their price target for agilon health from $1.23 to $1.23 per share. This reflects steady expectations for the company's valuation despite minor adjustments in forecasts for growth and margins.
What's in the News
- agilon health re-established earnings guidance for fiscal year 2025, projecting total revenues between $5,810 million and $5,830 million (Key Development)
Valuation Changes
- Consensus Analyst Price Target remains unchanged at $1.23 per share.
- Discount Rate is stable at 6.78 percent, showing no change.
- Revenue Growth forecast is nearly flat, moving from 7.54 percent to 7.54 percent.
- Net Profit Margin has fallen slightly, from 5.38 percent to 5.32 percent.
- Future P/E ratio has risen modestly, increasing from 1.60x to 1.62x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.